Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13428746 | 0.82 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL4093324 | 0.82 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL1325378 | 0.80 | LMNA (0.48) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL9789839 | 0.79 | LMNA (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL15376731 | 0.79 | LMNA (0.48) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL11318960 | 0.79 | LMNA (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL12760818 | 0.79 | LMNA (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL2944385 | 0.78 | ALDH1A1 (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL11214027 | 0.77 | LMNA (0.44) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL400210 | 0.77 | LMNA (0.44) | LMNAKMT2AMEN1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0475605-B1 | Phenolic resin and method for preparing same | MITSUI TOATSU CHEMICALS (JP) | 1996-01-03 | — | — | EP | claimed |
| EP-0164705-B1 | PROCESS FOR MANUFACTURING PHTHALALDEHYDACETALS | BASF Aktiengesellschaft (DE) | 1987-09-02 | — | — | EP | claimed |
| WO-2021126973-A1 | COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION | ORIONIS BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-7402708-B2 | Method for producing aqueous ortho-phthalaldehyde solutions | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2008-07-22 | — | — | US | disclosed |
| EP-1911830-A1 | Process for the reduction of sulfur, nitrogen and the production of useful oxygenates from hydrocarbon materials via one-pot selective oxidation | Kocat Inc. (KR) | 2008-04-16 | — | — | EP | disclosed |
| US-20060199870-A1 | acetal is converted into the o-phthalaldehyde by eliminating the corresponding alcohol; used in the sector of high-activity disinfection of endoscopes | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2006-09-07 | — | — | US | disclosed |
| US-7067288-B2 | Nucleotide sequences which code for the mdhA gene | DEGUSSA AG (DE) | 2006-06-27 | — | — | US | disclosed |
| US-6995002-B2 | Nucleotide sequences which code for the mdhA gene | DEGUSSA AG (DE) | 2006-02-07 | — | — | US | disclosed |
| EP-1297148-B1 | NUCLEOTIDE SEQUENCES WHICH CODE FOR THE MDHA GENE FROM CORYNEBACTERIUM GLUTAMICUM | DEGUSSA (DE) | 2005-12-14 | — | — | EP | disclosed |
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20040142454-A1 | Nucleotide sequences which code for the mdhA gene | DEGUSSA AG (DE) | 2004-07-22 | — | — | US | disclosed |
| EP-1297148-A1 | NUCLEOTIDE SEQUENCES WHICH CODE FOR THE MDHA GENE FROM CORYNEBACTERIUM GLUTAMICUM | Degussa AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | disclosed |
| US-20020037568-A1 | Nucleotide sequences which code for the mdhA gene | DEGUSSA AG (DE) | 2002-03-28 | — | — | US | disclosed |
| WO-2002002778-A1 | NUCLEOTIDE SEQUENCES WHICH CODE FOR THE MDHA GENE FROM CORYNEBACTERIUM GLUTAMICUM | DEGUSSA AG (DE) | 2002-01-10 | — | — | WO | disclosed |
| US-5078838-A | By electrochemical anodic oxidation of benzyl derivatives in the presence of an aliphatic alcohol | BASF AKTIENGESELLSCHAFT (DE) | 1992-01-07 | — | — | US | disclosed |
| US-4588482-A | Preparation of phthalaldehyde acetals | BASF AKTIENGESELLSCHAFT (DE) | 1986-05-13 | — | — | US | disclosed |
| US-4588482-A | Preparation of phthalaldehyde acetals | BASF AKTIENGESELLSCHAFT (DE) | 1986-05-13 | — | — | US | disclosed |
| US-4588482-A | Preparation of phthalaldehyde acetals | BASF AKTIENGESELLSCHAFT (DE) | 1986-05-13 | — | — | US | disclosed |
| EP-0164705-A2 | Process for manufacturing phthalaldehydacetals | BASF Aktiengesellschaft (DE) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | CETP, MTTP, LCAT | LMNA 4203/4885KMT2A 1440/4885MEN1 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.